P2Y\textsubscript{11} receptors: properties, distribution and functions

Charles Kennedy

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom

**Correspondence:** Dr. C. Kennedy, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom

Tel +44 (0)141 548 2664    Fax +44 (0)141 552 2562    E-mail c.kennedy@strath.ac.uk
Abstract
The P2Y₁₁ receptor is a G protein-coupled receptor that is stimulated by endogenous purine nucleotides, particularly ATP. Amongst P2Y receptors it has several unique properties; 1) it is the only human P2Y receptor gene that contains an intron in the coding sequence; 2) the gene does not appear to be present in the rodent genome; 3) it couples to stimulation of both phospholipase C and adenylyl cyclase. Its absence in mice and rats, along with a limited range of selective pharmacological tools, has hampered the development of our knowledge and understanding of its properties and functions. Nonetheless, through a combination of careful use of the available tools, suppression of receptor expression using siRNA and genetic screening for SNPs, possible functions of native P2Y₁₁ receptors have been identified in a variety of human cells and tissues. Many are in blood cells involved in inflammatory responses, consistent with extracellular ATP being a damage-associated signalling molecule in the immune system. Thus proposed potential therapeutic applications relate, in the main, to modulation of acute and chronic inflammatory responses.

Index keywords

2-methylthioADP 2-methythioATP ARC67085MX ADP
ADPβS Anti-inflammatory ATP ATPαS
ATPyS Biased agonism BzATP cAMP
Canine Cardiovascular cytokines DAMPs
dATP dendritic cells epithelia granulocytes
heteromultimer inflammation inositol phosphates intron
keratinocytes macrophages Mesenchymal cells NAADP⁺
NAD⁺ narcolepsy Natural killer cells Neutrophils
NF157 NF340 NF546 P2RY11
NF340
P2RY11/PPAN
UDP P2Y₁₁ receptor Polymorphisms SNPs

Indexing keywords
P2Y₁₁ receptor ATP NF157 NF340 NF546
1. Introduction

P2Y receptors are G protein-coupled receptors (GPCR) that are stimulated by the endogenous nucleotides, adenosine 5'-triphosphate (ATP), adenosine 5'-diphosphate (ADP), uridine 5'-triphosphate (UTP), uridine 5'diphosphate (UDP) and UDP-glucose. Eight human subtypes have been cloned (P2Y1,2,4,6,11,12,13,14) [1,2] and are expressed throughout the body [3-5]. The missing numbers represent non-mammalian orthologues or proteins proposed to be P2Y receptors, but at which the nucleotides were subsequently found to be inactive. The eight genuine P2Y subtypes show differential sensitivities to the endogenous agonists and the P2Y11 receptor is activated by ATP and ADP, but not the uridine nucleotides. In addition, the P2Y11 receptor has several unique properties; 1) it is the only human P2Y receptor gene that contains an intron in the coding sequence; 2) the gene does not appear to be present in the rodent genome; 3) it couples to stimulation of both phospholipase C (PLC) and adenylyl cyclase. Here, we will discuss these properties and review the pharmacological profile and possible physiological functions of the P2Y11 receptor.

2. Cloning and sequence of P2Y11 receptors

Humans The human P2Y11 (hP2Y11) receptor was first cloned from placenta using probes based on the nucleotide sequence of the P2Y4 receptor [6]. The P2RY11 gene (AJ298334) is on chromosome 19 (19p13.2) in humans, is 1125 base pairs long and codes a protein of 274 amino acids (CAC29362.1) [7]. Unlike all other P2Y subtypes, the gene has a 1.9 kb intron that separates two exons, which encode the first six amino acids and the rest of the receptor respectively. The P2Y11 protein has relatively low sequence identity with the other P2Y subtypes, ranging from 23% (P2Y14) to 34% (P2Y6) (Table 1). Multiple single nucleotide polymorphisms (SNPs) have been identified in the human genome and two of these, rs3745601 and rs2305795, will be discussed below when considering possible functions of P2Y11 receptors.

Initially, the P2RY11 receptor sequence was reported to comprise 1113 base pairs (AF030335), coding 371 amino acids (AAB88674.1), but subsequently, the same group reported that this cDNA sequence arose from intergenic splicing of the P2RY11 gene and that of PPAN, the human orthologue of Ssf1, a nuclear protein that is involved in mating in Saccharomyces cerevisiae, which lies adjacent and upstream [7,8]. The first P2RY11 exon was thus revealed to code for the protein sequence MAANVS, rather than MDR, as initially reported. The P2RY11/PPAN fusion transcript (AJ300588) lacks the first exon of P2RY11 and the last two thirds of the final exon in PPAN and is of unknown function. It appears to be expressed widely throughout the body and, as will be discussed below, this has been a problem when studying the distribution of P2RY11 mRNA.
Species orthologues  The canine P2RY11 receptor (NM_001204441) was subsequently cloned [9]. The gene is found in the same synteny as the human gene and the resultant protein has 70% amino acid sequence identity with the hP2Y11 receptor. An amphibian p2y receptor (AM040941) that has 35% amino acid sequence identity with the hP2Y11 receptor is proposed to be the species homologue of Xenopus [10]. Putative orthologues are identified in a number of other species in the NCBI HomoloGene database, but intriguingly, the gene does not appear where expected in the rat and mouse genomes and convincing P2RY11 mRNA transcripts have not been identified in rodent tissues [2,11,12]. Furthermore, it is unlikely that the gene has translocated to a different chromosomal region and can still be transcribed to produce a functional protein, as using the human sequence to search the UniProt protein database, Dreisig and Kornum, [12] found the closest match to be the P2Y1 receptor, at 32% similarity. This is the same degree of similarity as seen between the human P2Y1 and P2Y11 receptors (Table 1). Thus there is no evidence for expression of P2RY11 mRNA and P2Y11 protein in rodents that resemble those present in humans, which must be taken into account when considering pharmacological studies in rodent tissues, as will be discussed below.

3. Coupling of P2Y11 receptors to 2nd messenger systems

Direct activation of signalling pathways  As P2Y receptors are GPCR, they couple to heterotrimeric G proteins and in this respect they fall into two groups: the P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 subtypes couple mainly to Gαq/11, as indicated by a rise in cytoplasmic levels of inositol 1,4,5-trisphosphate (IP3) and related inositol phosphates (IPs), whilst the P2Y12, P2Y13 and P2Y14 receptors couple to Gαi/o [2,13]. The P2Y11 receptor is unique in that it couples to both Gαq/11 and Gαs [14]. When activated, Gαq/11 stimulates PLCβ, which cleaves phosphatidylinositol 4,5-bisphosphate in the plasma membrane into 1) IP3, which binds to IP3 receptors in the endoplasmic reticulum to release Ca2+ stores; and 2) diacylglycerol, which activates protein kinase C (PKC). Gαi can also bind to and activate the guanine nucleotide exchange factor, p63RhoGEF, which in turn stimulates Rho GTPases, such as RhoA [15]. Gαs, on the other hand, activates adenyl cyclase, leading to increased synthesis of cAMP and subsequently stimulation of protein kinase A.

Initially, ATP was reported to activate adenyl cyclase with similar [6] or greater potency [14] compared to PLC activation. The experiments were, however, carried out in different cell lines; 1321N1 human astrocytoma cells for IP accumulation and CHO-K1 cells for cAMP synthesis. Since agonist potency is greatly influenced by the level of receptor expression [16,17], the coupling of the hP2Y11 receptor to these signalling pathways was studied further in the same cell line [18]. In
1321N1 cells, ATP promoted IP accumulation with low µM potency (EC$_{50}$ = 8.5 ± 0.1 µM) and was 15-fold less potent in raising cAMP (EC$_{50}$ =130 ± 10 µM). In CHO-K1 cells, ATP evoked IP accumulation with slightly higher potency (EC$_{50}$ = 3.6 ± 1.3 µM) than in 1321N1 cells, but it was still 15-fold less potent in promoting cAMP synthesis (EC$_{50}$ = 62.4 ± 15.6 µM). Comparable differences in potencies for promoting the two second messenger responses were observed with other adenosine nucleotide analogues. Thus the P2Y$_{11}$ receptor appears to couple more effectively with the Go$_{q/11}$ signalling pathway than that of Go$_s$.

Indirect activation of adenylyl cyclase  It is important to note that some isoforms of adenylyl cyclase can be activated by PKC, independently of Go$_s$ [19]. For example, P2Y$_1$ receptors can activate PKCζ, which increases the activity of isoform 5 of adenylyl cyclase [20]. Such a mechanism does not appear to underlie the rise in cAMP mediated by P2Y$_{11}$ receptors, as inhibition of PKC did not suppress cAMP production elicited by stimulation of the canine P2Y$_{11}$ (cP2Y$_{11}$) receptor stably expressed in CF2Th cells [9]. Concomitant activation of PKC may, however, potentiate cAMP synthesis, as down-regulating PKC by chronic treatment with a phorbol ester decreased ATP-promoted cAMP accumulation by 60-80%, with no change in ATP’s potency, in both 1321N1 and CHO-K1 cells expressing the hP2Y$_{11}$ receptor [18]. Likewise, chelation of intracellular Ca$^{2+}$ decreased ATP-promoted cAMP accumulation by ~45% in 1321N1 cells, whereas chelation had no effect on either the efficacy or potency of ATP in CHO-K1 cells. Thus the capacity of the P2Y$_{11}$ receptor to elicit cAMP accumulation appears to be via Go$_s$, and this can be potentiated by the concomitant activation of PKC and mobilisation of intracellular Ca$^{2+}$ stores in a cell-type- and/or species subtype-dependent manner.

4. Pharmacological properties of P2Y$_{11}$ receptors

Agonists  The hP2Y$_{11}$ receptor is adenine nucleotide-prefering, with ATP more potent than ADP, whilst UTP, UDP and the nucleotide triphosphates, guanosine 5'-triphosphate (GTP), cytidine 5'-triphosphate, thymidine 5'-triphosphate and inosine 5'-triphosphate (ITP), are inactive [6,18,21]. The rank order of agonist potency for increasing either cAMP or IP$_s$ is ARC67085MX $\geq$ ATP$\gamma$S $\approx$ BzATP $> d$ATP $> ATP \approx 2$-methylthioATP $\approx$ ATP$\alpha$S $>$ ADP$\beta$S $>$ 2-methylthioADP $> ADP$ [6,14,18,22,23,24]. In addition, the diphosphates, ADP, ADP$\beta$S and 2-methylthioADP are partial agonists, with apparent efficacies of 60-80% of maximal response to ATP [23]. Note that ARC-C67085XX, the most potent P2Y$_{11}$ agonist, also antagonises P2Y$_{12}$ receptors [13], which limits its usefulness in characterising the functions of native P2Y$_{11}$ receptors. These studies all used the
original hP2Y\textsubscript{11} clone, in which the N terminal amino acid sequence begins MDR. When the receptor with the correct sequence, MAANVS, was expressed, there was, however, no significant difference in the potency of ATP and related molecules between the two isoforms [24].

Screening of a library of sulphonic and phosphonic acid derivatives identified NF546, a full agonist at hP2Y\textsubscript{11} receptors [24]. It is 2.5-fold less potent than ATP, but has a degree of selectivity over other P2Y subtypes as its EC\textsubscript{50} value at hP2Y\textsubscript{11} receptors was 28-fold, 102-fold and 604-fold lower than that at human P2Y\textsubscript{2}, P2Y\textsubscript{6} and P2Y\textsubscript{12} receptors respectively and it had little or no effect at human P2Y\textsubscript{1} and P2Y\textsubscript{4} receptors. Its activity at other P2X and P2Y subtypes has not been reported. Apparent agonist potency in bioassays depends, however, on the level of receptor expression, so whilst NF546 is a very useful tool for the pharmacological characterisation of native P2Y receptor subtypes, an action over a particular concentration range is not necessarily evidence for the presence of P2Y\textsubscript{11} receptors and an appropriate antagonist action profile and/or knockdown of the receptor using siRNA must also be obtained.

Nicotinamide adenine dinucleotide (NAD\textsuperscript{+}) and nicotinic acid adenine dinucleotide phosphate (NAADP\textsuperscript{+}), which both play important roles in intracellular signalling, are also hP2Y\textsubscript{11} agonists [25,26]. Furthermore, it has been suggested that NAD\textsuperscript{+} can be released from cells via connexin 43 hemichannels and so may act endogenously [27]. Note, however, that NAD\textsuperscript{+} also stimulates other P2 subtypes, including P2X1, P2X4, P2X7 and P2Y\textsubscript{1} receptors [28,29]. In addition, NAD\textsuperscript{+} can be metabolised to cyclic ADP-ribose, a potent agonist for release of intracellular Ca\textsuperscript{2+} stores [30], so a pharmacological effect of NAD\textsuperscript{+} cannot, on its own, be automatically taken as evidence for the expression of P2Y\textsubscript{11} receptors and again an appropriate antagonist action profile and/or knockdown of the receptor using siRNA must also be obtained.

**Antagonists** Suramin and PPADS are general, non-selective P2X and P2Y antagonists [5,31] and whilst suramin, at low µM concentrations, is a surmountable hP2Y\textsubscript{11} antagonist, PPADS is inactive [14,22]. The suramin analogue, NF157, is a competitive antagonist with pA\textsubscript{2} = 7.77, which makes it more potent than suramin, and it is at least 650-fold selective over P2Y\textsubscript{1} and P2Y\textsubscript{2} receptors [32]. In addition, NF157 is non-selective over P2X1 receptors and has low (P2X2, P2X3) to moderate (P2X4, P2X7) selectivity over other P2X subtypes [32]. Its activity at other P2X and P2Y subtypes has not been reported. These factors can limit its usefulness when studying native P2Y\textsubscript{11} receptors and care must be taken when using NF157 to obtain supporting data, such as lack of effect of a range of other P2X and P2Y antagonists and/or depression of receptor expression using tools such as siRNA.

Another suramin analogue, NF340, is also a competitive antagonist, with a pA\textsubscript{2} of 8.02 [24].
10 µM NF340 inhibited responses at recombinant human P2Y₁, P2Y₂, P2Y₄ and P2Y₆ receptors by less than 10% and so NF340 was calculated to have at least 520-fold selectivity over other P2Y receptors. Similarly, stimulation of recombinant human P2X1, P2X2 and P2X2/3 receptors was unaffected by 3 µM NF340. This compound may, therefore be more useful in determining the physiological functions of native P2Y₁₁ receptors, but again, its activity at other P2X and P2Y subtypes has not been reported and supporting data should be obtained.

UTP is not a biased agonist at P2Y₁₁ receptors  Biased agonism describes a multi-state model of GPCR activation in which each ligand induces a unique structural conformation of the receptor, such that the receptor couples differentially to G proteins and other intracellular proteins. For example, activation of the P2Y₂ receptor by UTP causes similar translocation of β-arrestin-1 and 2 from the cytoplasm to the plasma membrane, whereas ATP induced a greater translocation of β-arrestin-1 [33]. These differential effects of ATP and UTP had a downstream effect on cell signalling, as both agonists increased the levels of phosphorylated extracellular-signal regulated kinase, but the effect of UTP was transient, whereas that of ATP was prolonged.

As discussed above, all of the initial studies found UTP to be ineffective at raising IPs or cAMP in cells expressing hP2Y₁₁ receptors. A subsequent report proposed, however, that UTP was a biased P2Y₁₁ agonist, as it increased cytosolic [Ca²⁺], but did not induce accumulation of IPs, whereas ATP did both [34]. This was an intriguing proposal, so we studied the action of UTP at P2Y₁₁ receptors in greater detail [21].

We found that ATP evoked a rapid, concentration-dependent rise in intracellular Ca²⁺ with an EC₅₀ that was essentially the same as that reported by [34]. This is not surprising, as the 1312N1-hP2Y₁₁ cell line used in both studies was generated by the present author whilst on sabbatical at the University of North Carolina. Despite this, we did not observe a rise in intracellular Ca²⁺ when UTP was applied, even at 100 µM, a concentration that was almost maximally effective in the earlier study (Figure 1). Consistent with this, another group also failed to see a UTP-induced rise in intracellular Ca²⁺ levels in 1321N1 cells stably expressing the hP2Y₁₁ receptor [24]. Furthermore, we found that coapplying a high concentration of UTP with ATP did not inhibit either the rise in Ca²⁺ or IPs evoked by ATP (Figure 2), indicating that UTP does not bind to this receptor.

In contrast, UTP was slightly, but significantly more potent than ATP in evoking a rise in intracellular Ca²⁺ in 1321N1 cells stably expressing the human P2Y₂ receptor, with no difference in the maximum response. Thus the lack of response to UTP at hP2Y₁₁ receptors was not due to a problem with the UTP solution. So, contrary to the previous report, we found no evidence for an agonist action of UTP at the hP2Y₁₁ receptor, nor does UTP act as an antagonist. In our view the
most feasible explanation for the discrepancy in the activity of UTP is contamination of the UTP solution by a non-nucleotide agent acting at a receptor that is not a P2Y receptor in the earlier study.

cP2Y_{11} pharmacology  Interestingly, the cP2Y_{11} receptor is adenine diphosphate-preferring, with reported rank order of agonist potencies of $\text{ADP}\beta S = 2\text{-methylthioADP} \approx 2\text{-methylthioATP} >> \text{ADP} > \text{ATP}$ [9] and $2\text{-methylthioADP} > \text{ADP}\beta S > 2\text{-methylthioATP} > \text{ADP} > \text{ATP}\gamma S \geq \text{ATP}$ [23] for both IP and cAMP production. Furthermore, ADP, ADP$\beta S$ and 2-methylthioADP are full agonists [23]. Like the hP2Y_{11} receptor, UTP, UDP, GTP and ITP were inactive, and suramin, but not PPADS inhibited these responses.

The human and canine receptors have only 70% amino acid identity and a mutagenesis study targeted the arginine residue (Arg268) that is present at the junction between TM6 and the third extracellular loop of the hP2Y_{11} receptor, by replacing it with glutamine, which is present in the analogous position in the cP2Y_{11} receptor [23]. This change increased both the potency and efficacy of ADP relative to ATP, such that they were now nearly equipotent and equi-efficacious. Likewise, mutating the glutamine in the canine receptor to arginine increased the efficacy and potency of ATP relative to ADP, and they now had essentially identical potency and efficacy. Thus this single amino acid within the P2Y_{11} receptor is at least partially responsible for the species differences in its pharmacological properties.

Ligand binding site  Computational modelling and mutational analysis have provided insight to some of the amino acid residues that likely play a role in ligand binding. As noted above, Arg268 in the hP2Y_{11} receptor is at least partially responsible for the differences in the relative potency of ATP and ADP compared with at the canine orthologue [23]. This amino acid also plays a major role in agonist stereo-selectivity. The hP2Y_{11} receptor is preferentially activated by the Rp stereoisomer of ATP$\alpha S$, but mutating Arg268 to an uncharged residue caused the stereo-selectivity to be lost [35]. This mutational approach has also implicated arginine 106 and 307, glutamate 168 and alanine 313 in the ATP binding pocket [36]. Determination the three dimensional structure of the P2Y_{11} receptor through crystallisation or similar high resolution techniques is required, however, to confirm this.

5. P2Y_{1}/P2Y_{11} heteromultimers  
GPCR were long considered to be monomeric entities that couple to G proteins on a 1:1 stoichiometric basis. It is now clear, however, that GPCR, including P2Y receptors, can interact to
form dimeric or higher ordered oligomeric complexes, which may couple to one or more G proteins, with implications for the regulation of receptor subcellular localisation and trafficking, ligand binding and functional activity [37-40]. Constitutive formation of P2Y₁, P2Y₄, P2Y₆ and P2Y₁₂ homodimers has been shown using biochemical techniques [41,42,43] and publication of the crystal structure of the P2Y₁₂ receptor confirmed the latter [44]. Furthermore, different P2Y subtypes can interact physically to form function heterodimers, with altered pharmacological and signalling properties (see, for example, [45,46,47].

This is true also for the P2Y₁₁ receptor, which forms a complex with P2Y₁ receptor that has a greatly altered sensitivity to the antagonists, MRS2179 and NF157 [48]. In addition, the P2Y₁₁ receptor did not undergo agonist-induced endocytosis when expressed on its own, consistent with the early report that P2Y₁₁ receptors do not desensitise [14]. However, after cotransfection of the P2Y₁ subtype, ATP induced endocytosis of the P2Y₁₁ protein, which was not inhibited by the P2Y₁₁ antagonist NF157 [48]. The authors, therefore, concluded that agonist-induced endocytosis of the P2Y₁₁ receptor requires coexpression of the P2Y₁ receptor and in a subsequent study identified alanine 87 of the P2Y₁₁ receptor as playing a crucial role in the interaction with P2Y₁ receptors [49]. In addition, G protein receptor kinase 2 may also be required for P2Y₁₁ internalisation [33].

6. Expression of P2Y₁₁ receptors

mRNA expression Many studies using RT-PCR or northern blotting have reported detection of P2RY11 mRNA in a range of tissues and species [2], but this is complicated by the discovery that the P2RY11/PPAN fusion mRNA transcript is expressed widely (see [12] for an extensive overview). The latter transcript comprises the second exon of P2RY11 and most of the sequence of PPAN, so RT-PCR and northern blotting will only distinguish between the two sequences if one of the primers is designed to recognise at least part of the first exon of P2RY11 and/or part of the untranslated upstream sequence.

After a detailed and extensive review of the published literature, Dreisig and Kornum [12] identified only 5 papers out of 89 in which detection of the fusion transcript could confidently be discounted, all in human cells [50-54]. Thus it is clear that care must be taken when designing primers and that many reports that claimed to show P2RY11 mRNA expression need to be revisited and reviewed. The same group subsequently reported detection of P2RY11 mRNA in distinct regions of macaque monkey brain [55].

Protein expression The presence of mRNA may not necessarily mean that the corresponding protein is expressed, so it is essential to confirm protein expression using a selective antibody. This
approach has been used widely to study expression of all P2Y receptor subtypes, but in most cases the specificity of the antibody has not been unequivocally confirmed, for example, by showing that staining is absent in the appropriate receptor knock-out animal. Indeed, a commonly-used anti-P2Y\(_1\) antibody has been reported to be nonspecific [56] and we found that several commercially-available P2Y subtype antibodies show staining in 1321N1 cells, which do not express endogenous P2Y receptors (Kennedy, unpublished observations). Thus care must be taken when interpreting antibody staining data.

This holds true for data obtained using anti-P2Y\(_{11}\) antibodies, as a review of the published literature identified several issues with the commercially-available anti-P2Y\(_{11}\) antibodies [12]. Most of these target a region of the C-terminus of the receptor that has significant sequence similarity with the C-terminus of other P2Y subtypes, so there is a reasonable chance that this antibody may not be specific for the P2Y\(_{11}\) receptor. Although the predicted size of the P2Y\(_{11}\) protein is 40 kDa, western blot data from different groups, in which the most commonly used antibody (\#APR-015) was utilised, reported the molecular mass to be 33-60 kDa. All claimed that their band represented the monomeric P2Y\(_{11}\) receptor (see [12] for full details).

Anti-P2Y\(_{11}\) antibodies also bind proteins in rodent tissues [2,12], even though the P2RY\(_{11}\) gene is not present in the rodent genome, further casting doubt upon their specificity. An attempt to verify the specificity of three commercially-available anti-P2Y\(_{11}\) antibodies was made by first determining if they recognised the recombinant hP2Y\(_{11}\) receptor when expressed in a cell line [55]. One antibody that targeted the 3\(^{\text{rd}}\) cytoplasmic loop of the hP2Y\(_{11}\) receptor did not show any signal of the expected band size in western blots, but instead produced two bands of 142 and 195 kDa, including in untransfected cells. The other two antibodies, targeted against the 3\(^{\text{rd}}\) extracellular loop or the C-terminus, both produced multiple bands, including of the expected size. These two antibodies stained neuronal-like cells in macaque monkey brain, but an identical staining pattern was also seen in rat brain. Thus the specificity of these antibodies could not be validated.

Finally, the targeted C-terminus region is also present in the P2Y\(_{11}\)/PPAN fusion protein, which has a predicted size of 90 kDa, so that too will be detected by anti-P2Y\(_{11}\) antibodies. For example, an antibody generated against a sequence at the end of the P2Y\(_{11}\) C-terminus produced a band of around 90 kDa in western blots using CHO-K1 cells transfected with the P2RY\(_{11}\)/PPAN fusion plasmid, whereas transfection with the P2RY\(_{11}\) plasmid resulted in bands of around 45 kDa [7]. Transfection with the empty vector produced no bands.

7. Functions of P2Y\(_{11}\) receptors

Criteria for identifying receptor function  
Ideally, a comprehensive understanding of the
function of any receptor arises from characterisation of the effects of highly selective agonists and antagonists on cellular and tissue activity and correlation of these with the expression of its mRNA and protein and perhaps also with the effects of deleting the gene or suppressing translation of the mRNA. Unfortunately, since the P2RY11 gene appears to be absent in mice and rats, the species used in genetic deletion studies, it is not possible to produce P2Y_{11}-knock-out animals. In addition, as discussed above, doubt has been cast on the specificity of commercially-available anti-P2Y_{11} antibodies. Nonetheless, possible functions of native P2Y_{11} receptors have been identified in a range of non-rodent cells by applying two or more of the following criteria: a) detection of mRNA using appropriately designed primers; b) demonstration of appropriate effects of appropriate concentrations of NF546, NF157 and NF340; c) lack of effect of agonists and antagonists selective at other P2Y and P2X subtypes; d) inhibition of the proposed P2Y_{11} function by P2RY11 RNA interference. Detection of a band close to the predicted size of the P2Y_{11} receptor, ~40 kDa, in western blots, although not direct evidence in itself, might also be considered consistent with P2Y_{11} expression in a tissue.

Mostly, the proposed functions are based on single reports, though they may be supported by other studies in the same cell type in which only one of the above criteria are fulfilled. The majority of studies used siRNA knock-down of hP2Y_{11} receptors to support pharmacological data and many are in blood cells involved in immune responses, consistent with extracellular ATP being a member of the damage-associated molecular patterns (DAMPs) family [57].

Granulocytes β-NAD^{+} elicited rises in cytoplasmic Ca^{2+}, IP_{3} and cAMP in freshly isolated human granulocytes, which were inhibited by 1 μM NF157, (a concentration that is 50-times higher than the antagonist’s affinity for hP2Y_{11} receptors) and downregulation of P2Y_{11} expression by siRNA [25]. Furthermore, NF157 inhibited β-NAD^{+}-induced granulocyte chemotaxis and it was suggested that β-NAD^{+} is an endogenous hP2Y_{11} agonist and acts as a proinflammatory cytokine. Subsequently, similar effects were seen with another endogenous P2Y_{11} agonist, NAADP^{+} [26].

Neutrophils Human neutrophils undergo constitutive apoptosis, which was delayed by ATP, NAD^{+} and BzATP, but not UTP and appeared to be dependent upon cAMP activation of PKA [58], consistent with earlier reports of a P2Y_{11}-mediated increase in cAMP in human HL-60 cells, which are comprised mainly of neutrophil promyelocyte precursor cells [59,60]. The delay in apoptosis was inhibited by 500 nM NF157, but unaffected by P2X7 antagonism. Western blotting identified a protein of approximately 45 kDa. Similar results were reported in [61], which further demonstrated that the delay in neutrophil apoptosis was due to inhibition of the mitochondrial, but not the
extrinsic, pathway of apoptosis. Thus endogenous ATP, and possibly also NAD\(^+\), may act via P2Y\(_{11}\) receptors to increase neutrophil survival, which will prolong the inflammatory response and the ability of neutrophils to phagocytose and destroy foreign particles and invading microorganisms. Further supporting evidence is, however, required.

**Macrophages**  THP-1 cells are a human acute monocytic leukemia cell line that differentiate into the M1-proinflammatory type of macrophage after priming with lipopolysaccharide (LPS) and interferon-\(\gamma\). This was inhibited by apyrase, a soluble enzyme that dephosphorylates ATP, and by 50 \(\mu\)M NF157 [62]. This is a high concentration of NF157 (2,500-times greater than its \(K_B\) at P2Y\(_{11}\) receptors) and is enough to produce substantial blockade of numerous P2X and P2Y subtypes. THP-1 differentiation, was, however, unaffected by a range of other antagonists, PPADS (non-selective P2X and P2Y antagonist), NF449 (P2X1 antagonist), A438079 (P2X7 antagonist), MRS2179 (P2Y\(_{1}\) antagonist), MRS2578 (P2Y\(_{6}\) antagonist), clopidogrel (P2Y\(_{12}\) antagonist), MRS2211 (P2Y\(_{13}\) antagonist), consistent with NF157 acting here via P2Y\(_{11}\) receptors. Furthermore, THP-1 differentiation was also suppressed by down-regulation of P2Y\(_{11}\) receptors by specific siRNA.

LPS also induced the release of the pro-inflammatory cytokine, IL-6, and this too was inhibited by NF157 and P2Y\(_{11}\)-specific siRNA. Inhibition of adenylyl cyclase, similarly, depressed IL-6 release, consistent with IL-6 release being mediated by P2Y\(_{11}\) receptors. Based on these and other results, the authors concluded that LPS induces vesicular exocytosis of ATP from macrophage precursor cells, which then acts in an autocrine manner at P2Y\(_{11}\) receptors to cause these cells to differentiate into M1-pro-inflammatory macrophages that release pro-inflammatory cytokines, such as IL-6. In addition, they proposed that P2Y\(_{11}\) receptor antagonists might potentially be useful in the treatment of inflammatory diseases, such as sepsis.

**Dendritic cells**  The first clear evidence for functional expression of P2Y\(_{11}\) receptors in human dendritic cells was that the P2Y\(_{11}\) agonist, NF546, induced a rise in intracellular Ca\(^{2+}\) concentration that was abolished by NF340 [24], which is consistent with expression of P2RY11 mRNA in these cells [51]. In contrast to the studies above, which indicate pro-inflammatory roles for P2Y\(_{11}\) receptors, an anti-inflammatory role is indicated in human cultured, monocyte-derived dendritic cells [63]. Here, ATP and BzATP, but not ADP, UTP or UDP, induced dendritic cell maturation, which was inhibited by 10 \(\mu\)M NF340 and suramin, but unaffected by PPADS and P2X4 and P2X7 antagonists. In these cells, LPS caused release of the inflammatory cytokine, IL-12 and this was inhibited by ATP, an action that was reversed by both NF340 and down-regulation of P2Y\(_{11}\)
receptors by specific siRNA. Exposing dendritic cells to hypoxia for 5 hours, followed by reoxygenation, also suppressed the inhibitory effects of ATP and in addition, down-regulated $P2RY11$ mRNA. The authors proposed that this inhibition of $P2Y_{11}$ receptor activity may cause dendritic cells to become pro-inflammatory and so contribute to post ischaemia/reperfusion injury.

**Bronchial epithelial cells** The human bronchial epithelial cell lines, NuLi-1 and CuFi-1, are amongst the small number of cell types in which expression of $P2RY11$ mRNA has been demonstrated with confidence [53]. This group further showed that in these cells, lipoxin A4 (LXA$_4$), a regulator of adaptive immunity that has been proposed to reduce inflammation, acts by inducing ATP release, which in turn stimulates $P2Y_{11}$ receptors. In these cells, LXA$_4$ raised cytoplasmic Ca$^{2+}$ and cAMP, increased airway surface liquid height, induced cell proliferation and migration and improved wound repair, all of which were inhibited by NF340 (0.1-1 µM). In addition, knock-down of the $P2Y_{11}$ receptor using siRNA inhibited the increase in airway surface liquid height. Thus in this situation it is stimulation, rather than inhibition, of $P2Y_{11}$ receptors that is likely to be beneficial therapeutically.

**Keratinocytes** $P2Y_{11}$ receptor-mediated release of pro-inflammatory cytokines is also indicated in keratinocytes [64]. Interferon-γ induced IL-6 release from the human HaCaT keratinocyte cell line and this was inhibited by apyrase, suramin and NF157. The concentration of NF157 used, 100 µM, was very high, but IL-6 release was unaffected by a range of other antagonists; PPADS (non-selective P2X and P2Y antagonist), AZ10606120 (P2X7 antagonist), MRS2179 (P2Y$_1$ antagonist), MRS2578 (P2Y$_6$ antagonist), clopidogrel (P2Y$_{12}$ antagonist), MRS2211 (P2Y$_{13}$ antagonist). Furthermore, IL-6 release was also inhibited by down-regulation of $P2Y_{11}$ receptors using specific siRNA. Thus $P2Y_{11}$ receptors may play a role in inflammatory conditions of the skin, such as psoriasis and blocking them could facilitate skin repair.

**Mesenchymal cells** NAD$^+$ evoked rises in cytoplasmic Ca$^{2+}$, cAMP and cyclic ADP-ribose in human bone marrow-derived mesenchymal stem cells, which were all abolished by 1 µM NF157 [27]. Although alternative antagonists were not employed to rule out the involvement of other P2X and P2Y receptor subtypes, the effects of NAD$^+$ were also inhibited by $P2Y_{11}$ receptor down-regulation by siRNA, consistent with NAD$^+$ acting here via $P2Y_{11}$ receptors. In the same study, NAD$^+$ also induced NF157-sensitive chemotaxis of the mesenchymal cells, a small increase in cell proliferation, release of a variety of cytokines and increased nuclear translocation of a number of
cAMP/Ca^{2+}-dependent transcription factors. The cells also released NAD\(^+\) and ATP via connexin43 hemi-channels, suggesting that these nucleotides may act as endogenous modulators of mesenchymal cell function.

8. **P2RY11 polymorphisms as an indicator of function** Numerous SNPs of the P2RY11 gene are identified in the NCBI Single Nucleotide Polymorphism database and whilst their functional consequences are mostly unknown, genetic screening has implicated two SNPs in disease states.

**Cardiovascular disease** Genotyping of participants in the Malmo Diet and Cancer (MDC) study identified a small increased risk of acute myocardial infarction (AMI) in the A87T polymorphism (rs3745601) and the risk was greater in patients with a family history of AMI and/or early onset AMI [65]. In addition, patients in the MDC cardiovascular risk group had elevated plasma levels of C-reactive protein, a marker of inflammation and a strong prognostic factor for the development of AMI. Thus this P2Y\(_{11}\) polymorph appears to be associated with increased systemic inflammation and risk of cardiovascular disease.

Position 87 is near the extracellular end of the second transmembrane spanning region of the P2Y\(_{11}\) receptor and the P2Y\(_{11}\)A87T variant replaces a hydrophobic alanine residue with a polar threonine. How this could lead to the changes seen in the MDC cohort is unclear, but the A87T mutation had no effect on the potency and efficacy of BzATP compared with wild-type P2Y\(_{11}\) receptors expressed on their own, but BzATP became inactive when hP2Y\(_{11}\)A87T was coexpressed with P2Y\(_1\) receptors [49]. This was not mimicked by replacing A87 with serine or tyrosine. Additionally, the A87T mutation rendered the receptor insensitive to agonist-induced internalisation and the authors concluded that it disrupts the P2Y\(_1\)/P2Y\(_{11}\) heteromeric receptor interaction.

**Narcolepsy** Increasing evidence indicates that narcolepsy is an autoimmune disease that leads to a loss of hypocretin (orexin)-releasing neurones in the hypothalamus. Genome-wide association studies have identified a SNP (rs2305795) that is associated with narcolepsy in European and Asian [51], Chinese [66] and Japanese [67] patients. The SNP is in a region of the 3’ untranslated sequence of P2RY11 that appears to regulate transcription, as it correlated with substantially reduced expression of P2RY11 mRNA in CD8\(^+\) T lymphocytes and natural killer cells of the carriers, which in turn was associated with a reduced ability of P2Y\(_{11}\) receptors to inhibit ATP-induced monocyte cell death [51]. These data are consistent with roles for P2Y\(_{11}\) receptors in modulation of immune cell function, as discussed above.
9. **P2Y\textsubscript{11}-like receptors in rodents**  
   As discussed in section 2, the \textit{P2RY11} gene has not been identified in rodent genomes and careful analysis has failed to reveal good evidence for expression of \textit{P2RY11} mRNA and P2Y\textsubscript{11} protein in rodents that resemble those present in humans. Nonetheless, there is a body of reports that propose functional P2Y\textsubscript{11} receptor expression in rodent tissues. Some are based on the ability of ATP to raise cytosolic cAMP, but, as discussed in section 3, some isoforms of adenylyl cyclase can be activated independently of Go\textsubscript{s} and so an increase in cAMP cannot, on its own, be taken as evidence for P2Y\textsubscript{11} expression. In the main, the reports are based on pharmacological data using agonists, such as NAD\textsuperscript{+}, and/or NF157, as a supposedly selective P2Y\textsubscript{11} antagonist. As discussed in section 4, however, both compounds have multiple sites of action and should not be described as “selective”. Furthermore, no report has convincingly excluded these other sites from the effects of NAD\textsuperscript{+} or NF157 by using a variety of subtype-selective antagonists. In addition, data obtained using NF340 or NF546, which are more selective that NAD\textsuperscript{+} and NF157, cannot be supported by knock-down of the receptor by siRNA due to the lack of the \textit{P2RY11} gene. Consequently, until a solution to the apparent lack of \textit{P2RY11} gene in rodent genomes has been found, these receptors should, at best, only be termed P2Y\textsubscript{11}-like.

10. **Concluding remarks**  
   In the 20 years since the P2Y\textsubscript{11} receptor was first cloned, our knowledge and understanding of its properties and functions have improved relatively slowly. This has been, in part, due to its apparent absence in mice and rats, the most commonly used species for studying receptors and drug action and which prevent genetic deletion studies from being performed. In common with many other purinergic receptor subtypes, progress has also been hampered by the limited range of selective pharmacological tools. Nonetheless, by careful use of the available tools, along with suppression of receptor expression using siRNA and also genetic screening for SNPs, possible functions of native P2Y\textsubscript{11} receptors have been identified in a range of human cells and tissues. Many are in blood cells involved in inflammatory responses, consistent with extracellular ATP being a DAMP signalling molecule in the immune system. Thus proposed potential therapeutic applications relate, in the main, to modulation of acute and chronic inflammatory responses. Further study of these in animals will require the development of non-rodent models, whilst selective ligands with suitable pharmacokinetic properties are needed before potential trials in humans can go ahead. Regardless of these difficulties it is clear that the P2Y\textsubscript{11} receptor is a viable, novel therapeutic target.

**Conflicts of interest**
The author declares that he has no conflict of interests.

**Ethical approval**
This article does not contain any studies with human participants or animals performed by any of the authors.

**Abbreviations**
ADP - adenosine 5'-diphosphate
AMI - acute myocardial infarction
ATP - adenosine 5'-triphosphate
cP2Y_{11} receptor - canine P2Y_{11} receptor
DAMPs - damage-associated molecular patterns
GPCR - G protein-coupled receptors
GTP - guanosine 5'-triphosphate
hP2Y_{11} receptor - human P2Y_{11} receptor
IP_{3} - inositol 1,4,5-trisphosphate
IPs - inositol phosphates
ITP - inosine 5'-triphosphate
LXA_{4} - lipoxin A_{4}
MDC - Malmo Diet and Cancer
NAADP+ - nicotinic acid adenine dinucleotide phosphate
NAD+ - nicotinamide adenine dinucleotide (\) and
PKC - protein kinase C
PLC - phospholipase C
SNPs - single nucleotide polymorphisms
UDP - uridine 5'diphosphate
UTP - uridine 5'-triphosphate
References
13. Von Kügelgen I, Harden TK (2011) Molecular pharmacology, physiology, and structure of the
P2Y receptors. Adv Pharmacol 61:373-415


23. Qi AD, Zambon AC, Insel PA, Nicholas RA (2001) An arginine/glutamine difference at the juxtaposition of transmembrane domain 6 and the third extracellular loop contributes to the markedly different nucleotide selectivities of human and canine P2Y11 receptors. Mol Pharmacol 60:1375-1382


25. Moreschi I, Bruzzone S, Nicholas RA, Fruscione F, Sturla L, Benvenuto F, Usai C, Meis S,


48. Ecke D, Hanck T, Tulpurkar ME, Schäfer R, Kassack M, Stricker R, Reiser G (2008) Heterooligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and
ligand selectivity of the P2Y11 receptor. Biochem J 409:107-116


<table>
<thead>
<tr>
<th>Subtype</th>
<th>P2Y(_1)</th>
<th>P2Y(_2)</th>
<th>P2Y(_4)</th>
<th>P2Y(_6)</th>
<th>P2Y(_{11})</th>
<th>P2Y(_{12})</th>
<th>P2Y(_{13})</th>
<th>P2Y(_{14})</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2Y(_1)</td>
<td>-</td>
<td>38</td>
<td>44</td>
<td>46</td>
<td>32</td>
<td>24</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>P2Y(_2)</td>
<td>-</td>
<td>-</td>
<td>41</td>
<td>41</td>
<td>29</td>
<td>25</td>
<td>26</td>
<td>26</td>
</tr>
<tr>
<td>P2Y(_4)</td>
<td>-</td>
<td>-</td>
<td>43</td>
<td>32</td>
<td>25</td>
<td>26</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>P2Y(_6)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>34</td>
<td>24</td>
<td>24</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>P2Y(_{11})</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>22</td>
<td>21</td>
<td>23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2Y(_{12})</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>48</td>
<td>48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2Y(_{13})</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>47</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2Y(_{14})</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Human P2Y receptor subtype amino acid sequence identity
Figure Legends

Figure 1. ATP, but not UTP increases intracellular Ca^{2+} in 1321N1-hP2Y_{11} cells.

a) The superimposed traces show fluo-4 fluorescence during superfusion with ATP (10 μM) (upper trace) and UTP (100 μM) (lower trace) for 90 sec, as indicated by the horizontal bar. Both records are from the same population of cells. b) The mean peak amplitude of responses evoked by ATP (n=5) and UTP (10 μM, n=6 and 100 μM, n=12) are shown. Responses are expressed as % of the response to ATP (10 μM). Vertical lines show S.E.M. From Morrow et al., (2014).

Figure 2. UTP does not inhibit ATP-evoked responses in 1321N1-hP2Y_{11} cells.

a) The traces show the rise in intracellular Ca^{2+} evoked by ATP (2 μM) in the same population of cells before (left-hand side) and after superfusion for 10 min with UTP (100 μM) (right-hand side), as indicated by the horizontal bars. b) The mean peak amplitude of responses evoked by ATP (2 μM) in the absence and presence of UTP (100 μM, n=5) are shown. Responses are expressed as % of the control response to ATP (2 μM). c) The mean basal level of IPs (left-hand column) and the mean amplitude of responses evoked by ATP (3 μM) in the absence (middle column) and presence of UTP (100 μM) (right-hand column) are shown. n=3. Vertical lines indicate S.E.M. From Morrow et al., (2014).